Buy to Close your short position on GM   Today, GM shocked the market when the auto giant announced that its full year earnings will be in a range from $1 to $2. Compare this to the January guidance of $4 to $5 and you'll see why the stock is down more than 13% today.  Read More

BUY to Open the May 70 SLB Call Option (SLB+EN, at 5.40 or below)  Read More

Sell to close your March 45 Newmont Mining call option (NEM+CI) at the market. The yellow metal has been acting well of late and a result has pushed our call option into the money. But while the stock is higher now than when we entered the trade, the option's time value has eroded away, handing us a loss on the trade.  Read More

Buy Amylin Pharmaceuticals (AMLN) on margin.  the company expects to hear from the FDA regarding its smaller drug, Symlin; and on April 30th- regarding its drug exenatide. We expect at least one of these approvals to come through, and the stock price to react accordingly.  Because of the leverage, the trade is rated Medium Risk. Read More

BUY to Open the July 17.50 Call Option on Titan Corp. TTN (TTN+GW) at 1.75 or below.  Read More

BUY to CLOSE your CAI Mar 55 Put (CAI+OK) at the market.  We advise closing out your put position on CACI International (CAI) that we recommended on January 5th 2005.   Read More

BUY TO OPEN the Simon Property Group (SPG) July 60 Put (SPG+SL) at 2.30 or less.  Read More

SELL to Close the June 25 Call Option on PFE (PFE+FE) at market.  Read More

 BUY to CLOSE your eBAY April 37.50 Put (XBA+PU) at the market.  We advise closing out your position in eBAY put. We recommended selling a put on eBAY (EBAY) in mid-January after the stock dropped on what the Street had perceived as disappointing earnings. Read More

BUY to Open the June 25 Call Option on PFE (PFE+FE) at 1.90 or below  We recommend buying a call option on Pfizer (PFE) to capitalize on the today's decision of the FDA in favor of keeping its painkiller Celebrex on the market despite its cardiac risks. Read More